Amwill Health

Why is Amwill Health Care Ltd falling/rising?

As of 09-Aug, Amwill Health Care Ltd's stock price is at 41.50, reflecting a decline of 1.26%. The stock has significantly underperformed the Sensex over various time frames, with a year-to-date drop of 12.87% and a yearly decline of 31.27%.

As of 09-Aug, Amwill Health Care Ltd's stock price is falling, currently at 41.50, which reflects a decrease of 0.53 or 1.26%. The stock has underperformed compared to the benchmark Sensex, which has gained 0.52% over the past week. Over the past month, Amwill's stock has declined by 1.71%, while the Sensex has increased by 0.41%. Year-to-date, the stock is down 12.87%, significantly underperforming the Sensex's decline of 7.89%. Additionally, the stock has experienced a substantial drop of 31.27% over the past year, compared to the Sensex's modest decline of 2.63%.<BR><BR>Today's performance indicates that the stock has underperformed its sector by 1.38%. Despite showing some positive signs with a 150% increase in delivery volume on August 6, which suggests rising investor participation, the overall trend remains negative. The stock is trading higher than its 50-day, 100-day, and 200-day moving averages, but lower than its 5-day and 20-day moving averages, indicating some short-term weakness. Furthermore, the stock's erratic trading pattern, having not traded on one day out of the last 20, adds to the uncertainty surrounding its performance. Overall, these factors contribute to the ongoing decline in Amwill Health Care Ltd's stock price.

Which are the latest news on Amwill Health?

What does Amwill Health do?

Amwill Health Care Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 2017 and converted to a Public Limited Company in 2024. It currently has no reported sales or profits, with a market cap of INR 82 Cr and a P/E ratio of 8.00.

Overview: <BR>Amwill Health Care Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>Amwill Health Care Ltd was originally incorporated on August 21, 2017, under the name 'Amwill Health Care Private Limited'. The company later converted to a Public Limited Company, receiving a fresh Certificate of Incorporation on January 25, 2024. There is no sales or profit data reported for any specific quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 82 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 8.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.59 <BR>Return on Equity: 14.17% <BR>Price to Book: 1.02 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

How big is Amwill Health?

As of 10th June, Amwill Health Care Ltd has a market capitalization of 82.00 Cr, classified as a Micro Cap, with no available financial data for Net Sales and Net Profit for the latest four quarters. As of March 2025, Shareholder's Funds are at 69.22 Cr and Total Assets at 71.26 Cr.

As of 10th June, <BR><BR>Market Cap: Amwill Health Care Ltd has a market capitalization of 82.00 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds at 69.22 Cr and Total Assets at 71.26 Cr.

Who are the peers of the Amwill Health?

Amwill Health's peers include Pharmaids Pharma, Mercury Labs, Makers Labs, Bharat Immunolog, Bacil Pharma, Onyx Biotec, Vaishali Pharma, Vilin Bio Med, and Zenith Drugs. Amwill Health has excellent management and capital structure, with a 1-year return of -40.63%, better than Pharmaids Pharma but worse than Bacil Pharma's 23.76%.

Peers: The peers of Amwill Health are Pharmaids Pharma, Mercury Labs, Makers Labs, Bharat Immunolog, Bacil Pharma, Onyx Biotec, Vaishali Pharma, Vilin Bio Med, and Zenith Drugs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Mercury Labs and Amwill Health, while Average management risk is found at Onyx Biotec. Below Average management risk is noted for Pharmaids Pharma, Makers Labs, Bharat Immunolog, Vaishali Pharma, Vilin Bio Med, and Zenith Drugs, and the rest. Growth is Average at Amwill Health and Vilin Bio Med, while Below Average growth is seen at Pharmaids Pharma, Mercury Labs, Makers Labs, Bharat Immunolog, Bacil Pharma, Vaishali Pharma, and Zenith Drugs, and the rest. Excellent capital structure is noted at Mercury Labs and Amwill Health, while Average capital structure is found at Onyx Biotec, and Below Average capital structure is observed at Pharmaids Pharma, Makers Labs, Bharat Immunolog, Bacil Pharma, Vaishali Pharma, Vilin Bio Med, and Zenith Drugs, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bacil Pharma at 23.76%, while the lowest is Pharmaids Pharma at -52.99%. Amwill Health's 1-year return is -40.63%, which is higher than Pharmaids Pharma but lower than Bacil Pharma. Additionally, Bharat Immunolog and Vaishali Pharma have negative six-month returns.

When is the next results date for Amwill Health Care Ltd?

The next results date for Amwill Health Care Ltd is 30 May 2026.

The next results date for Amwill Health Care Ltd is scheduled for 30 May 2026.

Is Amwill Health overvalued or undervalued?

As of November 7, 2025, Amwill Health is considered undervalued with a PE ratio of 9.06 and strong return metrics, making it an attractive investment compared to peers like Sun Pharma and Dr Reddy's Labs.

As of 7 November 2025, Amwill Health's valuation grade has moved from fair to very attractive, indicating a significant improvement in its perceived value. The company is currently assessed as undervalued, with a PE ratio of 9.06, an EV to EBIT of 7.64, and an EV to EBITDA of 7.34. These ratios suggest that Amwill Health is trading at a discount compared to its peers in the pharmaceuticals and biotechnology sector.<BR><BR>In comparison, Sun Pharma is considered expensive with a PE ratio of 35.17, while Dr Reddy's Labs is attractive with a PE ratio of 17.43. This peer comparison highlights Amwill Health's favorable valuation position. Additionally, the company's return metrics are strong, with a ROCE of 18.23% and a ROE of 14.68%, further supporting the undervaluation narrative. Despite recent stock performance lagging behind the Sensex, the overall valuation suggests a compelling investment opportunity in Amwill Health.

How has been the historical performance of Amwill Health?

Amwill Health's historical performance shows fluctuating financial metrics, with net sales rising to 43.95 Cr in Mar'24 before declining to 40.58 Cr in Mar'25. Despite growth in total assets and improved cash flow, profitability metrics such as operating profit and profit after tax decreased in the latest fiscal year.

Answer:<BR>The historical performance of Amwill Health shows a fluctuating trend in key financial metrics over the past four years.<BR><BR>Breakdown:<BR>Amwill Health's net sales increased from 27.61 Cr in Mar'22 to 43.95 Cr in Mar'24, before declining to 40.58 Cr in Mar'25. Total operating income followed a similar pattern, rising to 43.95 Cr in Mar'24 and then decreasing to 40.58 Cr in Mar'25. The total expenditure also rose from 23.95 Cr in Mar'22 to 28.93 Cr in Mar'25. Operating profit, excluding other income, peaked at 16.67 Cr in Mar'24 but fell to 11.65 Cr in Mar'25. Profit before tax showed a similar decline from 16.76 Cr in Mar'24 to 11.90 Cr in Mar'25, while profit after tax decreased from 12.50 Cr to 10.73 Cr in the same period. The company's total assets grew significantly from 12.29 Cr in Mar'23 to 71.26 Cr in Mar'25, indicating a strong increase in shareholder's funds, which rose to 69.22 Cr by Mar'25. Cash flow from operating activities improved to 5.00 Cr in Mar'25, contrasting with a negative cash flow of -3.00 Cr in Mar'24. Overall, while Amwill Health experienced growth in assets and operating cash flow, its profitability metrics showed a decline in the most recent fiscal year.

Who are the top shareholders of the Amwill?

The top shareholders of Amwill include promoter Anand Gandhi with 31.64%, two Foreign Institutional Investors holding 1.16%, and public shareholder Varun Krishnavtar Kabra with 2.86%. Individual investors own 21.14% of the shares, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Amwill include the promoters, who hold the majority of the shares. The promoter with the highest holding is Anand Gandhi, owning 31.64% of the company. Additionally, there are two Foreign Institutional Investors (FIIs) that collectively hold 1.16%. The highest public shareholder is Varun Krishnavtar Kabra, with a stake of 2.86%. Individual investors also hold a significant portion, accounting for 21.14% of the shares. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

Has Amwill declared dividend?

No Dividend History Available